Small Cap Update: Northstar Gold, Candel Therapeutics, 374Water, BioVie, Ideal Power

Northstar Gold Corp. has extended its Cam Copper Mine's high-grade polymetallic system in Ontario, Canada, with new drill results showing significant down-plunge continuity and strong metal grades. Candel Therapeutics is advancing plans to commercialize its lead cancer immunotherapy, with new phase 3 trials and a planned regulatory filing. 374Water has received a purchase order from Garney Construction tied to a municipal project in Olathe, Kansas, marking a commercial step in deploying its technology to destroy PFAS-contaminated biosolids. BioVie's abstract for its SUNRISE-PD study has been accepted for presentation at the AD/PD 2026 annual meeting. Ideal Power is moving toward commercialization of its B-TRAN-enabled products, with strategic partnerships and agreements in place.